Kanada - Inggris - Health Canada

pharmel inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Kanada - Inggris - Health Canada

dominion pharmacal - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Kanada - Inggris - Health Canada

nu-pharm inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Kanada - Inggris - Health Canada

teva canada limited - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Kanada - Inggris - Health Canada

mylan pharmaceuticals ulc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Kanada - Inggris - Health Canada

sanis health inc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents

Uni Eropa - Inggris - EMA (European Medicines Agency)

teva pharma b.v. - leflunomide - arthritis, rheumatoid - immunosuppressants - leflunomide is indicated for the treatment of adult patients with active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard).recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - leflunomide 10mg - film coated tablet - 10 mg - active: leflunomide 10mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch povidone purified talc titanium dioxide - arava is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. arava is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; povidone; magnesium stearate; crospovidone; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions). lunava is not indicated for the treatment of psoriatic arthritis or psoriasis (whether or not associated with manifestations of psoriatic arthritis).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).